Notably, when TPL was combined with cisplatin (DDP), TPL significantly reduced the tumor burden and prolonged survival in mice through its ability to inhibit the polarization of M2 macrophages and downregulate the expression of CD31 and CD206. Here, MRC1 is linked to neoplasm.